Eli Lilly has agreed a major partnership with Insilico Medicine that could reach $2.75bn, as the US drugmaker accelerates its push into AI-developed medicines.
The deal gives Lilly rights to develop and commercialise a pipeline of therapies generated using Insilico’s artificial intelligence platforms and includes an upfront payment of roughly $115m, with additional payouts tied to development, regulatory and sales milestones, plus royalties on any approved drugs, according to Bloomberg.
The compounds involved are still in early-stage development, but the partnership reflects growing confidence in AI’s ability to reshape how medicines are discovered and brought to market. By using machine learning to identify targets and design molecules, companies aim to cut both timelines and costs compared with traditional lab-based approaches.
The Financial Times reported the collaboration may also involve access to a GLP-1-related asset, a class of drugs that has become one of the most lucrative areas in pharma due to soaring demand for diabetes and weight-loss treatments.
For Lilly, the move deepens an ongoing strategy to embed AI across its research pipeline as competition intensifies in high-growth therapeutic areas. The company has been actively forming partnerships that combine its clinical expertise with advanced computational tools.
For Insilico, the deal marks a significant commercial milestone, reinforcing investor confidence in its AI-led drug discovery model.
The agreement underscores a broader industry shift, as major pharmaceutical groups increasingly turn to AI not just as an experimental tool, but as a core driver of future drug development.
Choice anxiety, prestige bias, and the temptation to make selections based on outsourced confidence are just some of the parallels between investing and the world of wine tasting.
Regulators found Bank of America's monitoring software had a known flaw Merrill left uncorrected for years.
While AI has become a go-to research tool for affluent investors, new HSBC research suggests human advisors remain the deciding voice when investment decisions are made.
A 5-4 ruling preserves the Federal Reserve's independence for now, but the legal fight over presidential removal power is far from settled.
For years, large firms have been facing penalties and questions from regulators over interest rates for clients’ cash accounts.
Dan Biagini of American Equity says the steady decline of pensions, longer lifespans and a reset in interest rates are rewriting how advisors build retirement income
Direct indexing is on pace to outgrow ETFs and mutual funds. Northern Trust's Ken Lassner explains why the advisors who get it wish they had started sooner.
